ci 775
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 2, 2022 (NCT05475483)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Beta-2 adrenergic receptorINHIBITOR
ADRB2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(CCNCC(O)COc2cccc(C)c2)cc1OC- Mol. weight
- 345.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL314010 ↗
- ChEMBLCHEMBL2106060 ↗
Also known as
- bevantolol
- bevantolol
- bevantolol hcl
- bevantolol hydrochloride
- calvan
- calvan
- calvan
- calvan
- calvan
- ci 775
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05475483 | Phase 2 | Aug 2, 2022 | SOM Biotech SL |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| SOM Biotech SL | For profit | 1 | 1 | 1 | 2022 |
1 organizations
Page 1 / 1